Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

NCT00383214 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Epratuzumab
OTHER: Placebo

Sponsor

UCB Pharma